Table 3.

Subgroup univariable analysis of outcomes in patients treated with auto-HCT or CAR-T while in a PR in patients with known positive PET scan before treatment

Auto-HCT (N = 222)CAR-T (N = 126)
OutcomesN evalProb (95% CI)N evalProb (95% CI)P value
Nonrelapse mortality 215  119  .2* 
 100 d  3% (1-5)  2% (0-5) .5 
 1 y  6% (3-9)  3% (1-6) .1 
 2 y  7% (4-11)  3% (1-6) .04 
Progression/relapse 215  119  .007* 
 1 y  33% (27-39)  46% (36-55) .03 
 2 y  39% (32-46)  54% (42-66) .03 
Progression-free survival 215  119  .04* 
 1 y  61% (55-68)  52% (42-61) .1 
 2 y  54% (47-61)  43% (32-55) .1 
Overall survival 222  126  .005* 
 1 y  79% (73-84)  69% (60-77) .06 
 2 y  71% (65-77)  49% (34-63) .006 
Auto-HCT (N = 222)CAR-T (N = 126)
OutcomesN evalProb (95% CI)N evalProb (95% CI)P value
Nonrelapse mortality 215  119  .2* 
 100 d  3% (1-5)  2% (0-5) .5 
 1 y  6% (3-9)  3% (1-6) .1 
 2 y  7% (4-11)  3% (1-6) .04 
Progression/relapse 215  119  .007* 
 1 y  33% (27-39)  46% (36-55) .03 
 2 y  39% (32-46)  54% (42-66) .03 
Progression-free survival 215  119  .04* 
 1 y  61% (55-68)  52% (42-61) .1 
 2 y  54% (47-61)  43% (32-55) .1 
Overall survival 222  126  .005* 
 1 y  79% (73-84)  69% (60-77) .06 
 2 y  71% (65-77)  49% (34-63) .006 

N eval, number evaluated; Prob, probability.

*

Overall P values from the log-rank test (PFS and OS) and Gray’s test (NRM and Progression/relapse).

P values from the Wald-test given time.

or Create an Account

Close Modal
Close Modal